Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Swedish drug development company Medivir has partnered with SciLifeLab, a life science research firm, to identify compounds with the potential to inhibit SARS-CoV-2, the novel coronavirus that causes Covid-19.
The research collaboration will involve SciLifeLab’s Drug Discovery and Development Platform (DDD), which will gain access to Medivir’s protease-targeted compound library.
As part of the collaboration, the partners will work to identify the main protease of SARS CoV-2, Mpro, an essential non-structural protein needed for virus replication.